Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.

Cite this paper

@article{Stilgenbauer2016VenetoclaxIR, title={Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.}, author={Stephan Stilgenbauer and Barbara F. Eichhorst and Johannes Schetelig and Steven E. Coutr{\'e} and John Francis Seymour and Talha Munir and Soham D Puvvada and C M Wendtner and Andrew W Roberts and Wojciech Jurczak and Stephen Mulligan and Sebastian Boettcher and Mehrdad Mobasher and Ming Zhu and Monali B Desai and Brenda J. Chyla and Maria E Verdugo and Sari L Heitner Enschede and Elisa Cerri and Rod A. Humerickhouse and Gary Gordon and Michael J Hallek and William G. Wierda}, journal={The Lancet. Oncology}, year={2016}, volume={17 6}, pages={768-778} }